Physician profile
David Weitz
NPI 1306861588
$5,872.28
in general payments reported to CMS, 2019-2025
19 companies · $1,457 in 2025
The $1,457 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $222 · 2021: $433 · 2022: $681 · 2023: $1,246 · 2024: $1,120 · 2025: $1,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,823.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,778.91 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $1,650.06 | 2022-2025 | Infuse, Biotrue, Xiidra |
| Johnson & Johnson Vision Care, INC. | $424.10 | 2021-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $286.66 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $207.45 | 2020-2023 | |
| Alcon Vision LLC | $193.98 | 2019-2025 | Tryptyr |
| Harrow Eye, LLC | $191.57 | 2024-2025 | Vevye |
| Abbvie INC. | $180.72 | 2022-2025 | |
| Dompe US, INC. | $173.50 | 2020-2025 | Oxervate |
| Rxsight INC | $137.07 | 2022 | |
| Sun Pharmaceutical Industries INC. | $131.92 | 2021-2023 | Cequa |
| Aerie Pharmaceuticals, INC. | $129.75 | 2019 | |
| Astellas Pharma US INC | $125.00 | 2024 | Izervay |
| Oyster Point Pharma, INC. | $107.21 | 2023 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $75.23 | 2022-2025 | Acthar |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $21.70 | 2022 | |
| Biotissue Holdings INC. | $21.50 | 2021 | |
| Kala Pharmaceuticals, INC. | $19.17 | 2021 | |
| Eyevance Pharmaceuticals LLC | $16.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Weitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.